
Discovery of an Unnatural DNA Modification Derived from a Natural Secondary Metabolite

Graphical Abstract



Authors

Tong Wang, Rahul M. Kohli

Correspondence

rkohli@pennmedicine.upenn.edu

In Brief

In Wang and Kohli, 5-carboxymethylcytosine is revealed as an unnatural genomic DNA modification that can be generated *in vivo* from a unique combination of a sparse natural host metabolite and a neomorphic cytosine DNA methyltransferase.

Highlights

- Mutagenesis unexpectedly identifies a neomorphic activity in a DNA methyltransferase
- Bacterial genetics uncovers the modification 5carboxymethylcytosine (5cxmC)
- Structure-guided biochemistry reveals enzymatic basis for DNA carboxymethylation
- 5cxmC provides a model for how gain-of-function genomic bases may arise in nature







Brief Communication

Discovery of an Unnatural DNA Modification Derived from a Natural Secondary Metabolite

Tong Wang¹ and Rahul M. Kohli^{2,3,4,*}

- ¹Graduate Group in Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, PA, USA
- ²Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- ³Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA
- ⁴I ead Contact

*Correspondence: rkohli@pennmedicine.upenn.edu https://doi.org/10.1016/j.chembiol.2020.09.006

SUMMARY

Despite widespread interest for understanding how modified bases have evolved their contemporary functions, limited experimental evidence exists for measuring how close an organism is to accidentally creating a new, modified base within the framework of its existing genome. Here, we describe the biochemical and structural basis for how a single-point mutation in *E. coli*'s naturally occurring cytosine methyltransferase can surprisingly endow a neomorphic ability to create the unnatural DNA base, 5-carboxymethylcytosine (5cxmC), *in vivo*. Mass spectrometry, bacterial genetics, and structure-guided biochemistry reveal this base to be exclusively derived from the natural but sparse secondary metabolite carboxy-S-adenosyl-L-methionine (CxSAM). Our discovery of a new, unnatural DNA modification reveals insights into the substrate selectivity of DNA methyltransferase enzymes, offers a promising new biotechnological tool for the characterization of the mammalian epigenome, and provides an unexpected model for how neomorphic bases could arise in nature from repurposed host metabolites.

INTRODUCTION

Manipulation of genomes to accommodate non-canonical nucleobases creates opportunities for increasing DNA coding capacity and offers insights into the requirements for sustaining life (Krueger and Kool, 2009). Significant progress has been made in the propagation of unnatural nucleobases within the E. coli genome (Malyshev et al., 2014). Similarly, nonnative but naturally occurring nucleobases, such as those derived from bacteriophages, have been introduced into E. coli (Mehta et al., 2016a, 2016b). Both strategies rely on the manipulation of nucleoside triphosphate (dNTP) pools. Although dNTP manipulation is one way to imbue the genome with chemical diversity, marks covalently introduced after DNA replication provide an alternative route to encoding additional complexity in DNA, a strategy akin to nature's existing epigenetic bases. To our knowledge, there have been no previous reports describing an organism with an unnatural DNA modification derived from its own native metabolome, a finding that may show the feasibility for an organism to accidentally accrue a gain-of-function ability to create a new DNA base in vivo.

Within the natural realm, an array of different DNA modifications have been described, but the vast majority of this diversity is confined to bacteriophage genomes and their prokaryotic hosts. Modifications to all canonical nucleobases have been described in phages (Weigele and Raleigh, 2016). In prokaryotes, the predominant modifications are found at the *N*6 position of adenine and *N*4 or C5 positions of cytosine. Methylation of these bases primarily serves rudimentary functions to distinguish self from non-self in the arms race against bacteriophages (Nabel et al., 2012; Wilson and Murray, 1991), although emerging models suggest that some modifications may affect genome regulation (Sánchez-Romero and Casadesús, 2020).

5-Methylcytosine (5mC) is a genomic DNA modification that extends from prokaryotes to higher organisms. Phylogenetic evidence shows that DNA cytosine methyltransferases (MTases), the enzymes that make 5mC, are conserved from prokaryotic restriction-modification systems to eukaryotic gene regulatory machinery (lyer et al., 2011). In mammals, 5mC generation is largely confined to cytosine-guanine (CpG) dinucleotides (Portela and Esteller, 2010). Adding further complexity to this model, 5mC is a substrate for the ten-eleven translocation (TET) family enzymes, which iteratively oxidize 5mC to create 5-hydroxymethyl-, 5-formyl-, and 5-carboxylcytosine (He et al., 2011; Ito et al., 2011; Tahiliani et al., 2009). While predominantly implicated as intermediates toward 5mC erasure, the potential independent epigenetic identities of each oxidized 5mC base is the subject of numerous provocative hypotheses (Bilyard et al., 2020). Across phylogeny, there is therefore compelling evidence for a functional role for diverse DNA modifications, providing the motivation for understanding how new DNA modifications can arise.



CellPress


Cell Chemical Biology Brief Communication


1. Saturation Mutagenesis M.Mpel N374X Shows Activity Inconsistent with DNA Cytosine Methylation


(A) Mechanism of DNA cytosine methyltransferases

(B) Experimental design. Individual M.Mpel N374X constructs were transformed and expressed in E. coli. In vivo modification was detected by restriction digestion of purified plasmids. The CCGG sites recognized by HpaII or MspI are visualized by hash marks and include CpGs that could be modified. Partial resistance to cleavage at the site marked with a black arrow above the plasmid can result in the generation of a ~2-kb fragment highlighted with the red arrows on the gel.

(C) Hpall ("H," modification-sensitive) and Mspl ("M," methylation-insensitive) digestion. Each N374X mutant digestion pattern is WT-like, C135S catalytic mutant-like, or potentially neomorphic. The red arrows highlight MspI digestion bands inconsistent with methylation.







Here, we describe how our efforts to understand the structural basis of 5mC generation by the CpG MTase M.Mpel unexpectedly led to the identification of the previously undescribed DNA modification, 5-carboxymethylcytosine (5cxmC), which originates from the naturally occurring, trace secondary metabolite carboxy-S-adenosyl-L-methionine (CxSAM). Additional biochemistry and structure-guided rationalization led to the accurate prediction that E. coli's native MTase, Dcm, only requires a single-point mutation to generate 5cxmC as a metabolite-derived, unnatural nucleobase in genomic DNA in vivo, offering a model for how new modifications can arise in nature.

RESULTS

Saturation Mutagenesis of a CpG **MTase Reveals a New DNA** Modification


Given our interest in developing tools to understand mammalian modifications in the CpG context, we began by examining the crystal structure of a recently described bacterial CpG methyltransferase, M.Mpel (Wojciechowski et al., 2013). M.Mpel uses a canonical cytosine DNA MTase mechanism to make 5mC from S-adenosyl-L-methionine (SAM) and cytosine (Figure 1A). We focused on Asn374 of M.Mpel to assimilate two competing observations from the literature. The Asn side chain, which is heavily conserved across MTases, has been proposed to act as part of a network of hydrogen bonds with active site water molecules to promote the final elimination step for 5mC generation (Jurkowski and Jeltsch, 2011; Zhang and Bruice, 2006). Despite this model, however, mutation of this Asn to Ala is tolerated in homolo-

gous MTases and permits transfer of bulky SAM analogs in vitro (Lukinavicius et al., 2012). Thus, we pursued saturation mutagenesis of N374 as an unbiased way to understand its core role in MTase catalysis.

We performed an in vivo activity screen that relies upon the linkage of the M.Mpel mutant genotype with a cytosine-methylating phenotype. We separately transformed each of the 20 N374X variants, along with a C135S catalytic mutant, into E. coli. After inducing expression, the plasmids were recovered and assessed for the ability of each MTase to modify its own encoding plasmid in vivo (Figure 1B). Extracted plasmids were digested with one of two CCGG-recognizing restriction enzymes,

Brief Communication





Hpall and Mspl. Hpall is methylation sensitive and blocked by any covalent modification at the 5-position of the underlined cytosine. Its isoschizomer Mspl is methylation insensitive and was intended to serve as a positive control for methylation (Figure 1C).

In our in vivo screen, both the Hpall and Mspl digestion patterns were similar to wild-type (WT) M.Mpel for most of our variants, suggesting that conversion to C5mCGG was achieved across all plasmid sites. This finding suggests that, contrary to its postulated mechanistic role, N374 is generally tolerant to variation, although our saturating in vivo overexpression conditions and indirect assay may overestimate tolerance to mutagenesis. Nonetheless, partial protection from Hpall digestion, suggesting impaired catalysis, was observed with hydrophobic β-branched (Ile/Val), constrained (Pro), or bulky aromatic (Phe/Tyr/Trp) muta-

Figure 2. M.Mpel Mutants Create 5cxmC In Vivo

(A-C) Nucleoside LC-MS/MS of plasmid DNA modified in vivo by M.Mpel mutants. (A) Scanning mode identifies a candidate mass. Listed are the parent ion (MS1) m/z [M + H]⁺ associated with the fragment ion (MS2) [M + H - dR]⁺ resulting from loss of the deoxyribose sugar. (B) Quantitative detection normalized to input (T), expressed relative to maximum signal observed. (C) New modification shows a distinct retention time and detectable m/z in N374K but not WT M.Mpel plasmids. Peaks are normalized for maximal detection. Panels (A-C) show the same samples (n = 2 biological replicates). Error bars represent SD.

(D) CxSAM synthesized by CmoA in vivo provides a putative substrate for carboxymethylation.

(E) 5cxmC is derived exclusively from CxSAM as assessed by cmoA knockout (Δ). Shown is the % 5cxmC relative to total CpGs. Graphs show mean ± SD (n = 2 biological replicates). **Below limit of detection.

tions at position N374. Most notably and unexpectedly, in both positively charged variants, N374K and N374R, there emerged a faint ~2-kb band resistant to Mspl digestion, inconsistent with cytosine methylation (Figure 1C, red arrows). Upon reexamination of the plasmid map, we considered the possibility that if the CpG dinucleotides in the plasmid were to be randomly and partially modified to something other than 5mC in vivo, a CCGG protection event at a position between two larger fragments normally generated by Mspl digestion (Figure 1B, black arrow) could account for this new \sim 2-kb band (red arrows, Figure 1C, red).

Identification of 5cxmC

While Mspl cleaves at C5mCGG, it is blocked by bulkier modifications, such as the oxidized 5mCs (Liu et al., 2016). To explore the possibility that we were

detecting an unexpected DNA modification, we degraded each plasmid to its individual nucleosides and performed liquid chromatography-tandem mass spectrometry (LC-MS/MS), scanning for nucleoside masses larger than 5mC (Figure 2A). In the N374K and N374R mutants but not WT or C135S, we identified a peak with a unique retention time of 2.2 min and m/z 286.1 [M + H]⁺ \rightarrow 170.1 [M + H - dR]⁺ (Figures 2B and 2C).

Upon literature review, we identified carboxy-S-adenosyl-Lmethionine (CxSAM) as a candidate MTase substrate worth further investigation. CxSAM is a sparse secondary metabolite in E. coli generated from SAM and prephenate by the non-essential enzyme CxSAM synthase (CmoA) and has recently been shown to be involved in tRNA modifications of uridine in E. coli (Kim et al., 2013). Although CxSAM is 400-fold less prevalent than SAM in vivo (Kim et al., 2015), we noted that the reaction






Figure 3. M.Mpel N374K Creates 5cxmC In Vitro

(A) Unmodified pUC19 plasmid DNA was incubated with an excess of SAM or CxSAM and serial dilutions of M.Mpel WT or N374K. The negative control lane (*) contains the highest concentration of enzyme with no SAM or CxSAM substrate. Digestion with Hpall fragments only unmodified DNA. M.Mpel N374K transfers both CxSAM and SAM *in vitro* while M.Mpel WT only transfers SAM.

- (B) M.Mpel N374K prefers CxSAM over SAM in a quantitative oligonucleotide assay shown in Figure S3 (n = 3 independent replicates).
- (C) Mechanism of DNA carboxymethylation visualizing a π system, which is favorable for CxSAM electrophilicity. Adjacent to catalytic residues E184 and C135, N374K (blue) could form a gain-of-function salt bridge (dashed line) with the carboxylate (red) of CxSAM.
- (D) Structural model of M.Mpel with same elements as in (C). The model was obtained by the introduction of an N374K mutation and manually overlaying CxSAM from PDB: 4QNV in place of SAH in the 5-fluorocytosine (5flC)-bound M.Mpel structure (PDB: 4DKJ).

of CxSAM with a target cytosine would yield 5-carboxymethylcytosine (5cxmC) (Figure 2D), a bulky modification that could resist Mspl digestion. The nucleoside LC-MS/MS signal could also be consistent with this possibility: it has a more polar retention time relative to cytosine and 5mC, and the parent and fragmentation mass patterns fit with the addition of a carboxymethyl group.

To rigorously assess if CxSAM was in fact the substrate for our mutant MTase *in vivo*, we generated a *cmoA* knockout strain (Figures S1A–S1C). While *in vivo* plasmid carboxymethylation by M.Mpel N374K and N374R can be detected in the *cmoA*⁺ E. *coli* strain by LC-MS/MS, these signals are lost in the $\Delta cmoA$ strain (Figures 2D, S1D, and S2E). We also expressed M.Mpel WT, C135S, N374K, and a double mutant C135S N374K and showed that only the combination of M.Mpel N374K in cmoA⁺ E. *coli* could create an Mspl-resistant modification (Figure S1F). Thus, 5cxmC is generated via a similar mechanism to 5mC and is solely derived from the activity of mutant M.Mpel utilizing endogenous CxSAM as a substrate.

Validation of DNA Carboxymethyltransferase Activity

Having established the identity and origin of the 5cxmC base, we aimed to reproduce this activity *in vitro*. We purified both the WT and N374K M.Mpel variants (Figure S2A) and synthesized CxSAM as a diastereomeric mixture (Figures S2B–S2D). We then incubated the enzyme with a pUC19 plasmid DNA substrate and either SAM or CxSAM. The plasmids were subsequently digested with modification-sensitive Hpall (C**C**GG, 13 sites) (Figure 3A). Consistent with our *in vivo* analysis, WT M.Mpel is capable of completely protecting the pUC19 plasmid with SAM but not CxSAM. M.Mpel N374K, by contrast, transfers SAM less efficiently than the WT enzyme, but gains the neomorphic ability to transfer CxSAM.

For a more quantitative comparison of *in vitro* activity, we devised an oligonucleotide-based assay, whereby modification of a CpG on a fluorophore-labeled strand can be tracked by monitoring its resistance to Hpall digestion (Figure S3A). Consistent with the previous pUC19-based assay, we found that for WT M.Mpel, only SAM and not CxSAM was a substrate for cytosine modification. For the N374K variant, CxSAM was 1.3-fold preferred over SAM (Figures 3B, S3B, and S3C). While our *in vitro* studies show that N374K M.Mpel has a modest preference for CxSAM over SAM, our *in vivo* experiments suggest that the oligonucleotide assay may underestimate the extent of this preference, possibly due to our inability to separate CxSAM diastereomers or other factors that enhance CxSAM selectivity *in vivo*.

Structural Model Accurately Predicts Neomorphic Carboxymethylation by a Mutant *E. coli* MTase

Previous work with synthetic SAM analogs has suggested that transfer can be promoted by the presence of a conjugated π system at the β -carbon relative to the electrophilic carbon (Figure 3C) (Dalhoff et al., 2006). This mechanism alone, however, cannot explain why our mutant and WT M.Mpel behave differently toward the same CxSAM substrate. We thus turned to the crystal structure of M.Mpel with the S-adenosyl-L-homocysteine (SAH) product bound and manually overlaid CxSAM in place of SAH (Figure 3D). In the model, we observed that a mutant Lys374 is poised to form a potential salt bridge with the carboxylate anion of CxSAM, offering a likely explanation for this enzyme's ability to accept this substrate.

Given this structural model for cytosine carboxymethylation, we wondered if this neomorphic activity was also accessible for homologous MTases. We specifically chose to focus on *E. coli*'s naturally occurring DNA cytosine methyltransferase

Brief Communication






Figure 4. E. coli's Native Methyltransferase Dcm Is a Single Point Mutation Away from Accruing a Gain-of-Function Ability to Carboxymethylate Genomic DNA In Vivo, Redefining the Boundary between Unnatural and Natural Nucleobases

(A) Alignment of Dcm (purple, Swiss-Model: P0AED9) with M.Mpel (gray, PDB: 4DKJ).

(B and C) (B) Asn436 codon. (C) Qualitative nucleoside LC-MS/MS showing that only Dcm N436K can carboxymethylate E. coli genomic DNA in vivo. Peaks are normalized for maximal detection.

(D) Quantitative 5cxmC LC-MS/MS signal in Dcm mutants. Shown is the %5cxmC relative to total CCWGGs (W = A/T) with each Dcm variant (null = no plasmid). Error bars represent mean ± SD (n = 3 biological replicates). **Below limit of detection.

(E). Multiple routes to expanded genomic diversity are shown. Brown: unnatural dXTPs can be imported and replicated in vivo (Malyshev et al., 2014). Blue: nonnative nucleoside triphosphates (e.g., 5hmCTPs) can be incorporated into E. coli genomes using bacteriophage biosynthetic machinery (Mehta et al., 2016a, 2016b). Red: 5-carboxymethylcytosine (5cxmC) in DNA, synthesized by a neomorphic DNA-modifying enzyme, is a new, unnatural DNA base, derived from the native substrates cytosine and CxSAM, without dNTP manipulation.

(Dcm) because this enzyme allowed us to address the guestion: What does it take for an organism to make a new DNA modification, in vivo? While M.Mpel is native to Mycoplasma penetrans and generates 5mC in the CpG context, Dcm generates 5mC in CCWGG (W = A/G) contexts. Structural alignment showed that Asn436 of Dcm and Asn374 of M.Mpel are both positioned adjacent to C5 of the target cytosine (Figure 4A and 1A), and a simple transversion mutation in dcm could create an N436K mutation (Figure 4B).

Encouraged by our biochemical understanding of M.Mpelmediated DNA carboxymethylation, we moved to dam⁻/dcm⁻ E. coli and introduced either Dcm WT or N436K on a plasmid. After induction of MTase expression, we extracted the genomic DNA (gDNA) and performed nucleoside LC-MS/MS (Figure 4C). In this setting, both the WT and N436K enzymes could methylate cytosine. However, only the N436K mutant enzyme could create 5cxmC in the native E. coli genome. Quantification of 5cxmC showed that >1.5% of the CCWGG sites were carboxymethylated (Figure 4D). Thus, as with M.Mpel, despite the excess of SAM over CxSAM, a substantial amount of 5cxmC can be detected in vivo (Figure S4A). In addition, tracking E. coli growth curves for the Dcm WT, N436K, or C177A catalytic mutants suggests that the presence of 5cxmC does not lead to any apparent deficiency in growth under these conditions (Figure S4B).

To further compare with the M.Mpel variants, we next purified the Dcm WT and N436K mutant enzymes and assayed for their ability to modify pUC19 plasmid DNA with either SAM or CxSAM using the modification-sensitive restriction enzyme EcoRII (CCWGG, seven sites). Consistent with our in vivo observations, WT Dcm can protect the pUC19 plasmid with SAM but not CxSAM. By contrast, Dcm N436K has comparable ability to transfer both CxSAM and SAM (Figures S4C and S4D). Given the extensive conservation of the active site Asn in homologous MTases (Jurkowski and Jeltsch, 2011), the consistent findings from M.Mpel to Dcm indicate that this residue may have neomorphic potential across the cytosine MTase family. Our results highlight that a single-point mutation in the native dcm coding sequence is sufficient to create an unnatural DNA modification in E. coli.

DISCUSSION

Here, we describe the discovery of a new genomic DNA base derived exclusively from the combination of a neomorphic methyltransferase and a native, but sparse, metabolite. Although not our original intent, the realization that our findings occupy a distinct space relative to similar, yet methodologically divergent, synthetic biology efforts has afforded us unique insights into



both technology development and the chemical determinants of genomic composition and evolution (Figure 4E).

Non-canonical nucleobases can originate from a variety of sources. While previous efforts have shown that synthetic and non-native sources of dNTPs can be used to create new bases in vivo, this study instead identifies the metabolome as an underappreciated source of genomic diversification. Outside of SAM, metabolites have been well documented to potentiate (Blaschke et al., 2013; Chen et al., 2013) or inhibit (Dang et al., 2009; Xu et al., 2016) the production of naturally occurring modified nucleobases, but only very rarely are they considered as substrates that can directly be used to modify genomic DNA. An interesting exception is provided by ascorbic acid (vitamin C), which was recently shown to be an unexpected co-substrate for generating the natural, modified base 5-glycerylmethylcytosine in the algae Chlamydomonas reinhardtii (Xue et al., 2019). In the case of CxSAM, while no role in DNA modification was previously known, the metabolite has been shown to act as a direct substrate for modified uridines in tRNA (Kim et al., 2013, 2015) and small-molecule cofactor modifications (Serebryakova et al., 2016). These precedents helped us to reveal that CxSAM can also be utilized by neomorphic, mutant DNA MTases. Our study thus highlights the possibility that rare metabolites similar to CxSAM, with other biological functions, could be redirected toward the creation of new, modified nucleic acids, in agreement with previous phylogenetic predictions that invoked modified SAM substrates as possible sources for undiscovered genomic diversity (lyer et al., 2013).

Because CxSAM is a derivative of the parent metabolite SAM, substrate competition is a notable aspect of this study. This competition recapitulates a challenge faced in other synthetic biology efforts, outside of nucleic acids. For example, genetic code expansion can be limited by poor unnatural amino acid bioavailability and competition with endogenous elongation factor Tu (Chin, 2014). The experiments here establish that competition from a ubiquitous substrate (SAM) can be overcome. For technology development, this is an important observation because the synthetic SAM analog field continues to expand but is currently predominantly limited to in vitro settings. Given this study and others (Wang et al., 2013), it is now more feasible to consider whether SAM analogs with useful chemical handles can covalently modify DNA or proteins in vivo, despite their inevitable competition with native SAM.

As unnatural cytosines derived from SAM analogs have already been applied for in vitro sequencing applications (Kriukienė et al., 2013), the discovery of this DNA-modifying enzyme is also notable for its biotechnological potential. Here, we show that our enzyme can completely carboxymethylate a 2.6-kb plasmid substrate (Figure 3A). Given its proficiency, we speculate that our CpG DNA carboxymethyltransferase, which would selectively react with unmodified CpGs, can be leveraged to distinguish unmethylated, methylated, and oxidized CpGs when coupled to either third-generation or enzymatic methods for epigenetic sequencing (Figure S4E) (Schutsky et al., 2018).

Finally, we note that 5cxmC, but not 5mC, showed a gain-offunction ability to resist digestion by the modification-sensitive endonuclease Mspl (Figures 1C, S1D, and S1F). Given the growing body of evidence that suggests that restriction-modification systems have the capacity to coevolve, it is feasible that selection focused on 5cxmC could be harnessed to improve the stability and abundance of 5cxmC modifications in vivo (Iyer et al., 2011; Sánchez-Romero and Casadesús, 2020). However, we caution that the levels of 5cxmC remain relatively low $(\sim 1.5\%$ of possible sites in gDNA for Dcm N436K, Figure 4), and the neomorphic CxMTases not only can create 5cxmC from CxSAM but also have a diminished ability to create 5mC from SAM. Both properties have unknown and potentially independent effects on physiology that will require future investigation (Figure S4).

When considering the potential advantages of modified DNA bases, such as 5cxmC, it is particularly surprising that the answer to the question, "How close is an organism to accidentally procuring a new DNA modification?" may be only a point mutation. Interpreting this finding with knowledge of the extensive structural conservation within the cytosine MTase family and phylogenetic conservation of the enzyme CmoA illustrates how the boundary separating natural and unnatural DNA modifications is significantly more blurred than what might have been previously imagined.

SIGNIFICANCE

Efforts to manipulate and create synthetic organisms tolerant of unnatural or non-native nucleobases have collectively shown that life is remarkably accepting of new genomic chemistries. While these efforts have helped establish that exotic chemistries can be accommodated, here we describe and characterize a biochemical route for an unnatural DNA base to accidentally appear in vivo. We show that a single mutation in the active site of cytosine DNA methyltransferases confers neomorphic activity on these enzymes, allowing them to accept a sparse natural metabolite as a substrate and to thereby create 5-carboxymethylcytosine in genomic DNA. In addition to contributing a promising biotechnology for future exploration, our discovery of a host-derived, unnatural DNA modification provides evidence for the metabolome as a potentially rich and underappreciated source for accessing genomic diversity and offers a model for how new genomic DNA bases could arise in nature.

STAR*METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead Contact
 - Materials Availability
 - Data and Code Availability
- EXPERIMENTAL MODELS AND SUBJECT DETAILS
 - E. Coli Strains
- METHOD DETAILS
 - Cloning
 - In Vivo Methyltransferase Assays
 - Nucleoside LC-MS/MS
 - Protein Purification

Brief Communication



- CxSAM Synthesis
- Restriction Digest Based Assays
- pUC19 Assay
- Oligonucleotide Assay
- Protein Structures
- Growth Curves
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j. chembiol 2020 09 006.

ACKNOWLEDGMENTS

The authors thank Michael Cory, Juan Serrano, all members of the Kohli Laboratory, and Walraj Gosal (Cambridge Epigenetix, CEGX) for insightful discussions and feedback. In addition, we thank E. James Petersson for drawing our attention to the CxSAM metabolite, Mark Goulian and Kiran Gajula for assistance with bacteriology, Jamie DeNizio and Clementina Mesaros for providing mass spectrometry training and guidance, Uday Ghanty and Charles Ross III for CxSAM characterization support.

AUTHOR CONTRIBUTIONS

T.W. and R.M.K. designed the research and wrote the paper. T.W. performed all experiments.

DECLARATION OF INTERESTS

T.W. is supported by a Cambridge Epigenetix (CEGX) Training Fellowship. This work was supported by the NIH (R01-GM118501 and R01-HG010646 to R.M.K.). R.M.K. is supported by an Investigator in the Pathogenesis of Infectious Disease Award (Burroughs Wellcome Fund). Patent filing on the DNA carboxymethyltransferase is pending.

Received: April 28, 2020 Revised: August 19, 2020 Accepted: September 23, 2020 Published: October 13, 2020

REFERENCES

Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K.A., Tomita, M., Wanner, B.L., and Mori, H. (2006). Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, https://doi.org/10.1038/msb4100050.

Bilyard, M.K., Becker, S., and Balasubramanian, S. (2020). Natural, modified DNA bases. Curr. Opin. Chem. Biol. 57, 1-7.

Blaschke, K., Ebata, K.T., Karimi, M.M., Zepeda-Martinez, J.A., Goyal, P., Mahapatra, S., Tam, A., Laird, D.J., Hirst, M., Rao, A., et al. (2013). Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500, 222-226.

Chen, J., Guo, L., Zhang, L., Wu, H., Yang, J., Liu, H., Wang, X., Hu, X., Gu, T., Zhou, Z., et al. (2013). Vitamin C modulates TET1 function during somatic cell reprogramming. Nat. Genet. 45, 1504-1509.

Chin, J.W. (2014). Expanding and reprogramming the genetic code of cells and animals. Annu. Rev. Biochem. 83, 379-408.

Dalhoff, C., Lukinavicius, G., Klimasauskas, S., and Weinhold, E. (2006). Direct transfer of extended groups from synthetic cofactors by DNA methyltransferases. Nat. Chem. Biol. 2, 31-32.

Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744.

DeNizio, J.E., Liu, M.Y., Leddin, E.M., Cisneros, G.A., and Kohli, R.M. (2019). Selectivity and promiscuity in TET-mediated oxidation of 5-methylcytosine in DNA and RNA. Biochemistry 58, 411-421.

Engler, C., Kandzia, R., and Marillonnet, S. (2008). A one pot, one step, precision cloning method with high throughput capability. PLoS One 3, e3647.

He, Y.F., Li, B.Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011). Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303-1307.

Ito, S., Shen, L., Dai, Q., Wu, S.C., Collins, L.B., Swenberg, J.A., He, C., and Zhang, Y. (2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300-1303.

lyer, L.M., Abhiman, S., and Aravind, L. (2011). Natural history of eukaryotic DNA methylation systems. Prog. Mol. Biol. Transl. Sci. 101, 25-104.

lyer, L.M., Zhang, D., Burroughs, A.M., and Aravind, L. (2013). Computational identification of novel biochemical systems involved in oxidation, glycosylation and other complex modifications of bases in DNA. Nucleic Acids Res. 41, 7635-7655.

Jurkowski, T.P., and Jeltsch, A. (2011). On the evolutionary origin of eukaryotic DNA methyltransferases and Dnmt2. PLoS One 6, e28104.

Kim, J., Xiao, H., Bonanno, J.B., Kalyanaraman, C., Brown, S., Tang, X., Al-Obaidi, N.F., Patskovsky, Y., Babbitt, P.C., Jacobson, M.P., et al. (2013). Structure-guided discovery of the metabolite carboxy-SAM that modulates tRNA function. Nature 498, 123-126.

Kim, J., Xiao, H., Koh, J., Wang, Y., Bonanno, J.B., Thomas, K., Babbitt, P.C., Brown, S., Lee, Y., and Almo, S.C. (2015). Determinants of the CmoB carboxymethyl transferase utilized for selective tRNA wobble modification. Nucleic Acids Res. 43, 4602-4613.

Kriukienė, E., Labrie, V., Khare, T., Urbanavičiūtė, G., Lapinaitė, A., Koncevičius, K., Li, D., Wang, T., Pai, S., Ptak, C., et al. (2013). DNA unmethylome profiling by covalent capture of CpG sites. Nat. Commun. 4, 2190.

Krueger, A.T., and Kool, E.T. (2009). Redesigning the architecture of the base pair: toward biochemical and biological function of new genetic sets. Chem. Biol. 16, 242-248.

Kubiak, J.M., Culyba, M.J., Liu, M.Y., Mo, C.Y., Goulian, M., and Kohli, R.M. (2017). A small-molecule inducible synthetic circuit for control of the SOS gene network without DNA damage. ACS Synth. Biol. 6, 2067-2076.

Liu, M.Y., DeNizio, J.E., and Kohli, R.M. (2016). Quantification of oxidized 5methylcytosine bases and TET enzyme activity. Methods Enzymol. 573, 365-385.

Lukinavicius, G., Lapinaite, A., Urbanaviciute, G., Gerasimaite, R., and Klimasauskas, S. (2012). Engineering the DNA cytosine-5 methyltransferase reaction for sequence-specific labeling of DNA. Nucleic Acids Res. 40, 11594-11602.

Malyshev, D.A., Dhami, K., Lavergne, T., Chen, T., Dai, N., Foster, J.M., Corrêa, J., Ivan, R., and Romesberg, F.E. (2014). A semi-synthetic organism with an expanded genetic alphabet. Nature 509, 385-388.

Mehta, A.P., Li, H., Reed, S.A., Supekova, L., Javahishvili, T., and Schultz, P.G.(2016a). Replacement of 2'-deoxycytidine by 2'-deoxycytidine analogues in the E. coli genome. J. Am. Chem. Soc. 138, 14230-14233.

Mehta, A.P., Li, H., Reed, S.A., Supekova, L., Javahishvili, T., and Schultz, P.G. (2016b). Replacement of thymidine by a modified base in the Escherichia coli genome. J. Am. Chem. Soc. 138, 7272-7275.

Miller, J.H. (1992). A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria (Cold Spring Harbor Laboratory Press).

Mo, C.Y., Manning, S.A., Roggiani, M., Culyba, M.J., Samuels, A.N., Sniegowski, P.D., Goulian, M., and Kohli, R.M. (2016). Systematically altering bacterial SOS activity under stress reveals therapeutic strategies for potentiating antibiotics. mSphere 1, e00163-16.

Nabel, C.S., DeNizio, J.E., Carroll, M., and Kohli, R.M. (2017). DNA methyltransferases demonstrate reduced activity against arabinosylcytosine: implications for epigenetic instability in AML. Biochemistry 56, 2166-2169.



Nabel, C.S., Manning, S.A., and Kohli, R.M. (2012). The curious chemical biology of cytosine: deamination, methylation, and oxidation as modulators of genomic potential. ACS Chem. Biol. 7, 20-30.

Portela, A., and Esteller, M. (2010). Epigenetic modifications and human disease. Nat. Biotechnol. 28, 1057-1068.

Sánchez-Romero, M.A., and Casadesús, J. (2020). The bacterial epigenome. Nat. Rev. Microbiol. 18, 7-20.

Schutsky, E.K., DeNizio, J.E., Hu, P., Liu, M.Y., Nabel, C.S., Fabyanic, E.B., Hwang, Y., Bushman, F.D., Wu, H., and Kohli, R.M. (2018). Nondestructive, base-resolution sequencing of 5-hydroxymethylcytosine using a DNA deaminase. Nat. Biotechnol. 36, 1083-1090.

Serebryakova, M., Tsibulskaya, D., Mokina, O., Kulikovsky, A., Nautiyal, M., Van Aerschot, A., Severinov, K., and Dubiley, S. (2016). A Trojan-horse peptide-carboxymethyl-cytidine antibiotic from Bacillus amyloliquefaciens. J. Am. Chem. Soc. 138, 15690-15698.

Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., and Rao, A. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935.

Wang, R., Islam, K., Liu, Y., Zheng, W., Tang, H., Lailler, N., Blum, G., Deng, H., and Luo, M. (2013). Profiling genome-wide chromatin methylation with engineered posttranslation apparatus within living cells. J. Am. Chem. Soc. 135, 1048-1056.

Weigele, P., and Raleigh, E.A. (2016). Biosynthesis and function of modified bases in bacteria and their viruses. Chem. Rev. 116, 12655-12687.

Wilson, G.G., and Murray, N.E. (1991). Restriction and modification systems. Annu. Rev. Genet. 25, 585-627.

Wojciechowski, M., Czapinska, H., and Bochtler, M. (2013). CpG underrepresentation and the bacterial CpG-specific DNA methyltransferase M.Mpel. Proc. Natl. Acad. Sci. U S A 110, 105.

Xu, Q., Wang, K., Wang, L., Zhu, Y., Zhou, G., Xie, D., and Yang, Q. (2016). IDH1/2 mutants inhibit TET-promoted oxidation of RNA 5mC to 5hmC. PLoS One 11, e0161261.

Xue, J.H., Chen, G.D., Hao, F., Chen, H., Fang, Z., Chen, F.F., Pang, B., Yang, Q.L., Wei, X., Fan, Q.Q., et al. (2019). A vitamin-C-derived DNA modification catalysed by an algal TET homologue. Nature 569, 581-585.

Zhang, X., and Bruice, T.C. (2006). The mechanism of M.Hhal DNA C5 cytosine methyltransferase enzyme: a quantum mechanics/molecular mechanics approach. Proc. Natl. Acad. Sci. U S A 103, 6148-6153.





STAR***METHODS**

KEY RESOURCES TABLE

ER1821 E. coli NEB NYA dem'idam' E. coli NEB C29251 demOdam E. coli KEIO, Baba et al. 2006 JW1859 BR1821 JamoA This study NYA Chemicals, Peptides, and Recombinant Proteins HPI NEB R0171 Mspl NEB R0171 MSP Mspl NEB R0171 R06 Mspl NEB R0171 R06 Mspl NEB R0171 R06 Mildle NEB R01118 R06 R0118 R0118 R06 R0118 R06 R019 R06 R04 R06 R04 R06 R04 R06 R06 R04 R06 R06 R06 R06 R06	REAGENT or RESOURCE	SOURCE	IDENTIFIER
dcm//dam* E. coli NEB C2925I dcmod E. coli KEIO, Baba et al. 2006 JW1859 ER1821 demod This study N/A Chemicals, Peptides, and Recombinant Proteins Herital NEB R0171 Mspl NEB R0106 Hillidill-HE NEB R0106 Mildel NEB R01118 R01118 R01118 R0118 R01118 R0118 R01118 R01118	Bacterial and Virus Strains		
acmoA E. coli KEIO, Baba et al. 2006 JW1859 ER1821 acmoA This study N/A Chemicals, Peptides, and Recombinant Proteins Holl NEB R0171 Mspl NEB R0106 HIMM Mspl NEB R0106 HIMM HindIII-HF NEB R0111S R064 NEB R0111S EcoRII Thermo Fisher ER1921 Nucleoside Digestion Mix NEB M0649 N/A Mucleoside Digestion Mix NEB M0649 N/A MM NeB M0649 N/A Mucleoside Digestion Mix NEB M0649 N/A N/A N/A N/A N/A N/A N/A N/A M/A M/A M/A N/A N/A M/A	ER1821 <i>E. coli</i>	NEB	N/A
ER1821 Jamoa This study N/A Chemicals, Peptides, and Recombinant Proteins Horizonal Peptides, and Recombinant Proteins Hapall NEB R0171 Mapl NEB R0106 Mapl NEB R0111S CeoRII NEB R0111S EcoRIII Thermo Fisher ER1921 Nucleoside Digestion Mix NEB M0649 M.Mpel WT His This study N/A M.Mpel N374K His This study N/A Dom WT His This study N/A Dom W374K His This study N/A Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma A9384 Godocacetic acid Sigma A9384 CxSAM This study N/A Thymidine-D ₉ ITSD Toronto Research Chemicals T412002 Ortical Commercial Assays Diameterial Assays D460 Oligo Clean and Concentrator kit	dcm ⁻ /dam ⁻ E. coli	NEB	C2925I
Chemicals, Peptides, and Recombinant Proteins	∆cmoA E. coli	KEIO, Baba et al. 2006	JW1859
Hpall NEB R0171 Mspl NEB R0106 HindIII-HF NEB R3104 Note! NEB R3111S EcoRII Thermo Fisher ER1921 Nucleoside Digestion Mix NEB M0649 M.M. Mel WT His This study N/A M.M. Mpel N374K His This study N/A Dem W7 His This study N/A Dem N374K His This study N/A Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma A9384 Iodoacetic acid Sigma 4386 CxSAM This study N/A Thymidine-D ₃ ITSD Toronto Research Chemicals Tat2002 Critical Comercial Assays Toronto Research Chemicals Tat2002 Oligo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 G9504 Oligonucleotides	ER1821 <i>∆cmoA</i>	This study	N/A
Mspl NEB R0106 HindIII-HF NEB R3104 Ndel NEB R0111S EcoRII Thermo Fisher ER1921 Nucleoside Digestion Mix NEB M0649 M.Mpel WT His M16s study N/A Dem WT His This study N/A Dem N374K His This study N/A Proteinase K Zymo D3001 SAM NEB B9003S SAM NEB B9003S SAH Sigma A9384 lodocactic acid Sigma 43366 CxSAM This study N/A Thymidine-D _A TSD Toronto Research Chemicals T412002 Ortical Commercial Assays Toronto Research Chemicals 7412002 Oligo Clean and Concentrator kit Qiagen 69504	Chemicals, Peptides, and Recombinant Proteins		
Hindill-HF	Hpall	NEB	R0171
Ndel NEB R0111S EcoRIII Thermo Fisher ER1921 Nucleoside Digestion Mix NEB M0649 M.M. Mpel NT His This study N/A M.M. Mpel NT His This study N/A Dcm WT His This study N/A Dcm WT His This study N/A Dcm N374K His This study N/A Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma A9384 Iodoacetic acid Sigma A9384 CxSAM This study N/A Thymidine-D ₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays Oligo Clean and Concentrator kit Qiagen 69504 Oligo Clean and Concentrator kit Qiagen 69504 Oligo Clean and Concentrator kit Qiagen 69504 Oligonucleotides IDT N/A 27-Top-C-FAM: ID N/A	Mspl	NEB	R0106
EcoRII Thermo Fisher ER1921 Nucleoside Digestion Mix NEB M0649 M.Mpel NT His This study N/A M.Mpel N374K His This study N/A Dem WT His This study N/A Dem N374K His This study N/A Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma A9384 Iodoacetic acid Sigma 14386 CxSAM This study N/A Thymidine-D ₃ ITSD Torto Research Chemicals TVA Critical Commercial Assays Tricitical Commercial Assays TV Oligo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 Oligonucleotides TV N/A T27-Top-C-FAM: IDT N/A GTATCTAGTTCAATCAGCAFAM IDT N/A 27-Exbtom-mC: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATA	HindIII-HF	NEB	R3104
Nucleoside Digestion Mix NEB M0649 M.Mpel WT His This study N/A M.Mpel N374K His This study N/A Dcm WT His This study N/A Dcm W374K His This study N/A Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma A9384 lodoacetic acid Sigma A9384 lodoacetic acid Sigma A9384 lodoacetic acid Sigma 43966 CxSAM This study N/A Thyrridine-D ₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays Oligo Clean and Concentrator kit Qiagen 27104 gDNA extraction kit Qiagen 27104 9DNA gDNA extraction kit Qiagen 69504 Oligonucleotides 27-Top-C-FAM: IDT N/A GTATCTAGITCAATCGGATTGAACTAGATAC IDT N/A 27-Bottom-C:	Ndel	NEB	R0111S
M.Mpel WT His This study N/A M.Mpel N374K His This study N/A Dcm WT His This study N/A Dcm N374K His This study N/A Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma 4384 Iodoacetic acid Sigma 14386 CxSAM This study N/A Thymidine-D3 ITSD Toronto Research Chemicals T412002 Critical Commercial Assays Toronto Research Chemicals T412002 Critical Commercial Assays June D4060 Plasmid extraction kit Qiagen 27104 9094 Oligonucleotides June P104 9094 27-Top-C-FAM: IDT N/A GTCATAGAAC/SmC/GGATTGAACTAGATAC IDT N/A 27-Bottom-C: IDT N/A TGCTATGAACCAGATTGAACTAGATAC This study N/A 27-CxmC-standard This study N/A<	EcoRII	Thermo Fisher	ER1921
M.Mpel N374K Hils This study N/A Dcm WT Hils This study N/A Dcm N374K Hils This study N/A Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma A9384 Iodoacetic acid Sigma I4386 CxSAM This study N/A Thyrnicine-D ₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays O0ligo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides 27-To-C-FAM: IDT N/A GTATCTAGATCAGTCAGCA-FAM IDT N/A 27-Bottom-C: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATAC IDT N/A 27-Eottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC This study N/A 27-cxmC-standard This study	Nucleoside Digestion Mix	NEB	M0649
Dom WT His This study N/A Dom N374K His This study N/A Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma A9384 lodoacetic acid Sigma I4386 CxSAM This study N/A Thymidine-D ₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays Toronto Research Chemicals T412002 Critical Commercial Assays D4060 D4060 Digo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides 27-Top-C-FAM: IDT N/A GTATCHACTCAGTCAGTAGCA-FAM 27-Eottommc: IDT N/A TGCTATGAAC/SmC/GGATTGAACTAGATAC IDT N/A 27-Bottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC This study N/A 27-cxmC-standard </td <td>M.Mpel WT His</td> <td>This study</td> <td>N/A</td>	M.Mpel WT His	This study	N/A
Dcm N374K His This study N/A Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma A9384 lodoacetic acid Sigma H386 CxSAM This study N/A Thymidine-D ₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays Toronto Research Chemicals T412002 Critical Commercial Assays Use of Commercial Assays D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides Use of Commercial Assays N/A 27-Top-C-FAM: IDT N/A GTATCTAGTTCAATCCGGTTCATAGCA-FAM USE of Commercial Assays N/A 27-Bottom-mC: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATAC USE of Commercial Assays N/A 27-Eottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC This study N/A 27-cxmC-standard <td>M.Mpel N374K His</td> <td>This study</td> <td>N/A</td>	M.Mpel N374K His	This study	N/A
Proteinase K Zymo D3001 RNAse A Thermo EN0531 SAM NEB B9003S SAH Sigma A9384 lodoacetic acid Sigma I4386 CxSAM This study N/A Thymidine-D ₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays Toronto Research Chemicals T412002 Critical Commercial Assays D4060 D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides T7-Top-C-FAM: IDT N/A 27-Top-C-FAM: IDT N/A 27-Top-C-FAM: IDT N/A 27-Ebottom-mC: IDT N/A 27-Bottom-mC: IDT N/A TGGTATGAAC/5mC/GGATTGAACTAGATAC This study N/A 27-cxmC-standard This study N/A Recombinant DNA Miniprepped from NEB C2925I N/A PUC19 Miniprepped from NEB C2925I N/	Dcm WT His	This study	N/A
RNAse A Thermo EN531 SAM NEB B9003S SAH Sigma A9384 lodoacetic acid Sigma I4386 CxSAM This study N/A Thymidine-D ₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays Oligo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 27104 gDNA extraction kit IDT N/A GTATCTAGTTCAATCCGGTTCATAGCA-FAM IDT N/A GTATCTAGTTCAATCCGGTTGAACTAGATAC 27-Bottom-C: IDT N/A TGCTATGAAC/SmC/GGATTGAACTAGATAC 27-Bottom-C: TGCTATGAACTAGATAC 27-CxmC-standard TDA Recombinant DNA PUC19 Miniprepped from NEB C29251 N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	Dcm N374K His	This study	N/A
SAM NEB B9003S SAH Sigma A9384 Iodoacetic acid Sigma I4386 CxSAM This study N/A Thymidine-D ₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays T412002 Oligo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides UDT N/A 27-Po-C-FAM: IDT N/A GTATCTAGTTCAATCCGGTTCATAGCA-FAM IDT N/A 27-Bottom-mC: IDT N/A TGCTATGAAC/SmC/GGATTGAACTAGATAC IDT N/A 27-Bottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC 27-cxmC-standard This study N/A Recombinant DNA WIA N/A pUC19 Miniprepped from NEB C2925I N/A Software and Algorithms Www.graphpad.com	Proteinase K	Zymo	D3001
SAH Sigma A9384 Iodoacetic acid Sigma I4386 CxSAM This study N/A Thymidine-D3 ITSD Toronto Research Chemicals T412002 Critical Commercial Assays Under the commercial Assays Oligo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides Under the commercial Actor of th	RNAse A	Thermo	EN0531
Iodoacetic acid Sigma I4386 CxSAM This study N/A Thymidine-D₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays T412002 Oligo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides UDT N/A 27-Top-C-FAM: IDT N/A GTATCTAGTTCAATCCGGTTCATAGCA-FAM UDT N/A 27-Bottom-mC: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATAC UDT N/A 27-cxmC-standard This study N/A Recombinant DNA Miniprepped from NEB C29251 N/A Software and Algorithms Graphpad www.graphpad.com	SAM	NEB	B9003S
This study N/A Thymidine-D ₃ ITSD Toronto Research Chemicals T412002 Critical Commercial Assays Oligo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides 27-Top-C-FAM: IDT N/A GTATCTAGTTCAATCCGGTTCATAGCA-FAM 27-Bottom-mC: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATAC 27-Bottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC 27-cxmC-standard This study N/A Recombinant DNA pUC19 Miniprepped from NEB C29251 N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	SAH	Sigma	A9384
Thymidine-D ₃ ITSD Toronto Research Chemicals Total Conference Toronto Research Chemicals Toronto Res	lodoacetic acid	Sigma	I4386
Critical Commercial Assays Zymo D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides UDT N/A 27-Top-C-FAM: IDT N/A GTATCTAGTTCAATCCGGTTCATAGCA-FAM IDT N/A 27-Bottom-mC: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATAC IDT N/A 27-Bottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC V/A N/A 27-cxmC-standard This study N/A Recombinant DNA Miniprepped from NEB C2925I N/A Software and Algorithms Graphpad www.graphpad.com	CxSAM	This study	N/A
Oligo Clean and Concentrator kit Zymo D4060 Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides 27-Top-C-FAM: IDT N/A GTATCTAGTTCAATCCGGTTCATAGCA-FAM IDT N/A 27-Bottom-mC: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATAC IDT N/A 27-Bottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC IDT N/A 27-cxmC-standard This study N/A Recombinant DNA Miniprepped from NEB C2925I N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	Thymidine-D ₃ ITSD	Toronto Research Chemicals	T412002
Plasmid extraction kit Qiagen 27104 gDNA extraction kit Qiagen 69504 Oligonucleotides 27-Top-C-FAM: IDT N/A GTATCTAGTTCAATCCGGTTCATAGCA-FAM 27-Bottom-MC: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATAC IDT N/A 27-Bottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC This study N/A 27-cxmC-standard This study N/A Recombinant DNA pUC19 Miniprepped from NEB C2925I N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	Critical Commercial Assays		
gDNA extraction kit Qiagen Giagen G	Oligo Clean and Concentrator kit	Zymo	D4060
Oligonucleotides 27-Top-C-FAM: IDT N/A GTATCTAGTTCAATCCGGTTCATAGCA-FAM 27-Bottom-mC: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATAC 27-Bottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC 27-cxmC-standard This study N/A Recombinant DNA pUC19 Miniprepped from NEB C29251 N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	Plasmid extraction kit	Qiagen	27104
27-Top-C-FAM: GTATCTAGTTCAATCCGGTTCATAGCA-FAM 27-Bottom-mC: TGCTATGAAC/5mC/GGATTGAACTAGATAC 27-BottomC: TGCTATGAACCGGATTGAACTAGATAC 1DT N/A TGCTATGAACCGGATTGAACTAGATAC 1DT N/A TGCTATGAACCGGATTGAACTAGATAC 27-cxmC-standard This study N/A Recombinant DNA pUC19 Miniprepped from NEB C29251 N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	gDNA extraction kit	Qiagen	69504
GTATCTAGTTCAATCCGGTTCATAGCA-FAM 27-Bottom-mC: IDT N/A TGCTATGAAC/5mC/GGATTGAACTAGATAC 27-BottomC: IDT N/A TGCTATGAACCGGATTGAACTAGATAC 27-cxmC-standard This study N/A Recombinant DNA pUC19 Miniprepped from NEB C29251 N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	Oligonucleotides		
TGCTATGAAC/5mC/GGATTGAACTAGATAC 27-Bottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC 27-cxmC-standard This study N/A Recombinant DNA pUC19 Miniprepped from NEB C29251 N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	27-Top-C-FAM: GTATCTAGTTCAATCCGGTTCATAGCA-FAM	IDT	N/A
27-Bottom-C: IDT N/A TGCTATGAACCGGATTGAACTAGATAC 27-cxmC-standard This study N/A Recombinant DNA pUC19 Miniprepped from NEB C2925I N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	27-Bottom-mC: TGCTATGAAC/5mC/GGATTGAACTAGATAC	IDT	N/A
Recombinant DNA pUC19 Miniprepped from NEB C2925I N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	27-Bottom-C: TGCTATGAACCGGATTGAACTAGATAC	IDT	N/A
pUC19 Miniprepped from NEB C2925I N/A Software and Algorithms Prism 8 Graphpad www.graphpad.com	27-cxmC-standard	This study	N/A
Software and Algorithms Prism 8 Graphpad www.graphpad.com	Recombinant DNA		
Software and Algorithms Prism 8 Graphpad www.graphpad.com	pUC19	Miniprepped from NEB C2925I	N/A
Prism 8 Graphpad www.graphpad.com			
	Prism 8	Graphpad	www.graphpad.com
	Fiji	This study	https://fiji.sc/

RESOURCE AVAILABILITY

Lead Contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rahul Kohli (rkohli@pennmedicine.upenn.edu).



Materials Availability

Plasmids generated in this study can be obtained with a Materials Transfer Agreement.

Data and Code Availability

This study did not generate any datasets/code.

EXPERIMENTAL MODELS AND SUBJECT DETAILS

E. Coli Strains

ER1821 *E. coli* (New England Biolabs (NEB), F⁻ *glnV44* e14⁻ (*McrA*⁻) *rfbD1? relA1? endA1 spoT1? thi-1* Δ(*mcrC-mrr*)114::/S10) were used in M.Mpel experiments, including cloning. This strain is void of all methylation-specific restriction factors which recognize CpG methylation as foreign. ER1821 Δ*cmoA* was created with P1vir phage transduction using the Δ*cmoA* strain (JW1859) from the KEIO collection and kanamycin selection (Figures S1A–S1C) (Baba et al., 2006; Miller, 1992). For Dcm experiments, *dcm*⁻/*dam*⁻ *E. coli* were used (NEB C2925I, *ara-14 leuB6 fhuA31 lacY1 tsx78 glnV44 galK2 galT22 mcrA dcm-6 hisG4 rfbD1 R(zgb210::Tn10)* Tet^S *endA1 rspL136* (Str^R) *dam13::Tn9* (Cam^R) *xylA-5 mtl-1 thi-1 mcrB1 hsdR2*).

METHOD DETAILS

Cloning

The WT M.Mpel sequence was obtained from the protein FASTA file from the deposited (PDB: 4DKJ) crystal structure (Wojciechowski et al., 2013) and ordered as an *E. coli* codon-optimized GeneBlock from Integrated DNA Technologies (IDT). The gene was PCR amplified with primers containing Bsal-HF and HindIII-HF overhangs using Phusion Polymerase (NEB) and ligated into digested pMG81 plasmid, a medium copy number vector with an anhydrotetracycline-inducible promoter (Kubiak et al., 2017). The WT *dcm* gene was obtained by directly amplifying from ER1821 gDNA with Phusion Polymerase and primers introducing a C-terminal His tag and appropriate Bsal overhangs. This gene was then assembled using Golden-Gate cloning (Engler et al., 2008) into a compatible pMG81 plasmid. All mutations were obtained by performing Q5 Site Directed Mutagenesis (NEB) and confirmed by Sanger sequencing.

In Vivo Methyltransferase Assays

Individual pMG81-MMpel or pMG81-Dcm plasmids were transformed into chemically-competent E.~coli and plated separately. Single colonies were grown in cultures (3 mL LB, 100 μ g/mL carbenicillin). Cultures were allowed to grow at 37°C until log phase (OD \sim 0.4-0.7) before induction with 20 ng/mL anhydrotetracycline (ATc) and then grown overnight. Plasmid extractions (Qiagen) or gDNA extractions (Qiagen DNeasy) were then performed, eluted in 10 mM Tris-Cl, pH 8.0, and quantified by nanodrop.

Nucleoside LC-MS/MS

Plasmid or gDNA was digested with Nucleoside Digestion Mix (NEB) in a 10 μ L total volume for 4 hours at 37°C, and the mixture was diluted 10-fold into 0.1% formic acid with the addition of 770 fmol thymidine-D₃ (T-D₃) internal standard (ITSD) into a volume of 20 μ L. LC-MS/MS was performed as previously described (DeNizio et al., 2019). Briefly, 5 μ L was injected onto an Agilent 1200 Series HPLC instrument equipped with a 5 μ m, 2.1 mm \times 250 mm Supelcosil LC18-S analytical column (Sigma) equilibrated to 45°C in buffer A (0.1% formic acid). The nucleosides were separated in a gradient of 0 to 10% buffer B (0.1% formic acid and 30% (v/v) acetonitrile) over 8 min at a flow rate of 0.5 mL/min. MS/MS was performed by positive ion mode ESI on an Agilent 6460 triple-quadrupole mass spectrometer, with a gas temperature of 225°C, a gas flow of 12 L/min, a nebulizer at 35 psi, a sheath gas temperature of 300°C, a sheath gas flow of 11 L/min, a capillary voltage of 3500 V, a fragmentor voltage of 70 V, and a delta EMV of 1000 V. Energies were 10 V for all bases except for 5cxmC (25V). When scanning in multiple reaction monitoring (MRM) mode, mass transitions were collected in increments of two mass units from 242.1 \rightarrow 126.1 to 300.1 \rightarrow 184.1. For targeted MRM, mass transitions were (C: 228.1 \rightarrow 112.1, T: 243.1 \rightarrow 127.1, T-D₃: 246.1 \rightarrow 130.1, 5mC: 242.1 \rightarrow 126.1, 5cxmC: 286.1 \rightarrow 170.1). The amount of total input DNA injected was first obtained using T and the T-D₃ ITSD using the equations below, where A signifies area measured by the MS/MS instrument. This number was then used to calculate a relative quantity of 5cxmC nucleoside in the experiments that lack a chemical standard for 5cxmC. This approach allows for accurate comparisons across conditions and is used in Figures 2A–2C.

fmol
$$T = 192.5$$
 fmol $T \frac{A_T}{A_{T-D_3}}$

Relative 5cxmC (arbitrary units) =
$$\frac{A_{\text{5cxmC}}}{\text{fmol }T}$$

A standard for 5cxmC was synthesized using a chemoenzymatic approach. Excess M.Mpel N374K was reacted with CxSAM and hemimethylated substrate (see Oligonucleotide Assay methods). The substrate was verified for complete carboxymethylation by Mspl digestion and visualized for fluorescein (FAM) fluorescence (excitation at 488 nm, emission at 520 nm) after separation on a



20% TBE Acrylamide Denaturing PAGE. The fully carboxymethylated standard was purified using an oligonucleotide spin column (Zymo), and quantified using the FAM fluorophore. This purified hemi-carboxymethylated oligonucleotide was then digested with Nucleoside Digestion Mix (New England Biolabs) in a 10 μL total volume for 4 hours at 37°C and diluted 10-fold into 0.1% formic acid before LC-MS/MS injection. An LC-MS/MS standard curve with serial dilutions of digested nucleoside (Figures S1D and S1E) was used to convert the integrated area of an experimental sample to fmol 5cxmC detected. The lowest concentration on the LC-MS/MS standard curve was determined to be the limit of detection (0.26 fmol Figures 2 and 4).

With knowledge of the amount of T and 5cxmC injected, it was possible to calculate the total amount of 5cxmC relative to either total CpG sites (M.Mpel) or CCWGG sites (Dcm, W = A/T). For M.Mpel experiments, the amount of T injected was converted to total amount of CpGs injected by dividing by the molar ratio of Ts to CpGs in the pMG81-MMpel plasmid (5.07). For Dcm samples, the complete genome of K-12 MG1655, the parent strain of the $dam^{-}/dcm^{-}E$. coli strain (GenBank: U00096.3) was analyzed. The molar ratio (101) comparing total instances of T (2,284,124) to CCWGG (22,716) was used to calculate the total amount of 5cxmC relative to total CCWGG sites.

Protein Purification

All variants were purified using a C-terminal His tag. Single colonies from transformation of pMG81-MMpel, pMG81-M.Mpel-N374K, pMG81-Dcm, or pMG81-Dcm-N436K into ER1821 *E. coli* were started in overnight cultures (10 mL LB, 100 μ g/mL carbenicillin), inoculated into large scale cultures (1 L LB, 100 μ g/mL ampicillin) in the morning, and allowed to grow at 37°C until log phase (OD \sim 0.4 - 0.7) before switching the temperature to 16°C. After 20 minutes, 20 ng/mL anhydrotetracycline (ATc) was used to induce protein overexpression and cultures were left at 16°C overnight. Cells were harvested by centrifugation (8000g, 30 min, 4°C) before resuspending in 25 mL Buffer A (50 mM Tris Cl, pH 7.5 at 25°C, 150 mM NaCl, 25 mM Imidazole, 10% Glycerol (v/v)) + 1 EDTA-free Protease Inhibitor Tablet (Sigma) + 10 μ L RNase A (Thermo Fisher). Resuspended cells were frozen overnight at -80°C.

Cells were lysed using a sonicator and centrifuged at 4°C for 30 min at 27,000g. Soluble lysate was passed through a gravity column containing 4 mL His Cobalt Resin, pre-equilibrated in Buffer A. After loading, the columns were washed with 25 column volumes (CV) of Buffer A for WT M.Mpel and WT Dcm, or 25 CV of Buffer B (50 mM Tris Cl, pH 7.5 at 25°C, 1 M NaCl, 25 mM Imidazole, 10% Glycerol (v/v)) followed by 5 CV of Buffer A for M.Mpel N374K and Dcm N436K. Protein was eluted with sequential fractions of Buffer C (50 mM Tris Cl, pH 7.5 at 25°C, 150 mM NaCl, 150 mM Imidazole, 10% Glycerol (v/v)). Samples were dialyzed (8,000 MWCO, Thermo Fisher) overnight at 4°C in 2 L of prechilled Dialysis Buffer (20 mM Tris HCl pH 7.5 at 25°C, 0.2 mM EDTA, 2 mM DTT, 150 mM NaCl, 10% Glycerol (v/v)). Cold 40% (v/v) glycerol was added to the protein to dilute the dialyzed protein 2-fold before flash freezing with liquid nitrogen and long-term storage at -80°C. All proteins were quantified by comparison to a BSA standard curve after running SDS-PAGE and visualizing with Coomassie Blue.

CxSAM Synthesis

Reactions were performed as previously described (Kim et al., 2015). 2-iodoacetic acid (667 mg) was added to a solution of S-adenosyl-L-homocysteine (20 mg) in 3.3 mL of 150 mM aqueous ammonium bicarbonate. The reaction was incubated at 37° C for 24 hrs. 80 mL of methanol was then added and incubated at 4° C overnight. Precipitates were collected by centrifugation at 4° C (2000g, 30 min) and washed twice with cold methanol to yield CxSAM. CxSAM was dissolved in nuclease free water and stored at -20° C. We attempted purification using a Zorbax 300SB-C18 column (9.4 x 250 mm, 5 μ m particle size) (Agilent Technologies) with Buffer A = 10 mM Na₂HPO₄, pH 5.9 and Buffer B = 100% acetonitrile as described previously (Serebryakova et al., 2016). The absence of other products under these conditions suggested that no further purifications were necessary (Figure S2). CxSAM was quantified using absorbance measured at 260 nm (15,400 L mol⁻¹ cm⁻¹). High resolution mass spectrometry (HRMS) was obtained to 443.1360 (mDa = -0.2, PPM = -0.5, Theoretical Mass: 443.1343).

Restriction Digest Based Assays

Restriction digestions were performed at 37°C for 1 hr in 1x NEB CutSmart Buffer in the specified volume. EcoRII restriction digests were performed at 37°C for 1 hr in 1x Thermo Scientific Buffer O.

pUC19 Assay

3-fold serial dilutions of M.Mpel (0.78 μ M – 3.2 nM) were incubated with 160 μ M SAM or CxSAM substrate and pUC19 plasmid DNA (100 ng) for 4 hrs at 37 °C in M.Mpel reaction buffer (10 mM Tris Cl, 50 mM NaCl, 1 mM DTT, 1 mM EDTA, pH 7.9 at 25 °C) in a 5 μ L volume. 2.5 μ L of the reaction was then incubated with the appropriate restriction enzyme, and the plasmid DNA was simultaneously linearized with HindIII-HF (NEB) in a final digestion volume of 25 μ L. Hpall (NEB) recognizes CCGGs (13 sites). Samples were treated with 1 μ L Proteinase K at 37 °C for 10 min, separated on 1% TAE Agarose gel, and visualized with SYBR Safe DNA Gel Stain (Thermo-Fisher).

A similar assay was performed with the Dcm proteins except that serial 3-fold dilutions encompassed 0.26 μ M – 3.2 nM and activity was instead assessed with EcoRII (Thermo), which recognizes CCWGGs (7 sites). The plasmid was also linearized with Ndel (NEB).

Oligonucleotide Assay

A FAM labelled top strand oligonucleotide with a single unmethylated CCGG and unlabeled complementary bottom strand oligonucleotides with an unmethylated or methylated CCGG were obtained from IDT as above. 200 nM of the duplexed, hemimethylated



oligo was reacted with serial dilutions of M.Mpel and 40 μM SAM or CxSAM substrate at 37°C in M.Mpel reaction buffer and a final volume of 5 μL for 30 min before heat inactivation at 95°C for 5 min. 25x excess of unmethylated bottom strand was reannealed before restriction digestion with Hpall in a final volume of 50 µL (Nabel et al., 2017). Undigested and digested strands were resolved on a 20% TBE Acrylamide Denaturing PAGE. In vitro carboxymethylation was also confirmed by purifying the reaction mixture before the strand exchange step with an Oligo Clean & Concentrator column (Zymo) and analyzing by electrospray ionization mass spectrometry (ESI-MS, Novatia, Figure S3).

Protein Structures

The structure of M.Mpel bound to SAH and a 5-fluorocytosine containing DNA substrate was used in modeling (PDB 4DKJ). The mutant N374K residue was manually created in PyMOL. Subsequently, CxSAM (PDB 4QNV) was manually overlaid on top of SAH with no energy minimization calculations to determine bond angles.

Growth Curves

dam /dcm E. coli were transformed with pMG81-Dcm expression plasmids and plated on amplicillin. Overnight cultures were started from single colonies. The next morning, cultures were quantified by OD₆₀₀ before dilution (LB, 100 μg/mL carbenicillin). Protein overexpression was induced with or without ATc (20 ng/mL). Cultures were monitored for 20 hours at 37°C with cycled agitation (3-mm orbital shaking, 450 rpm) in a 96-well plate (Mo et al., 2016). Optical density at 595 nm (OD₅₉₅) measurements were obtained every 5 minutes on a plate reader (Tecan).

QUANTIFICATION AND STATISTICAL ANALYSIS

All replicates are explicitly specified within figure legends.

FAM-labelled gels were quantified on a Typhoon imager and using Fiji software. Curves in Figure S3 were fit using GraphPad Prism 8 using non-linear least squares fit to extract EC₅₀ values and 95% confidence intervals.

Cell Chemical Biology, Volume 28

Supplemental Information

Discovery of an Unnatural DNA Modification

Derived from a Natural Secondary Metabolite

Tong Wang and Rahul M. Kohli

Supplemental Figures:




Figure S1, related to Figure 2: Validation of CmoA knockout and LC-MS/MS standard. (A) CmoA catalyzes the reaction between SAM and prephenate to yield water, CxSAM, and phenylpyruvate (Kim et al., 2013). (B) Transduction with bacteriophage P1vir was used to move a kanamycin resistance cassette from KEIO ΔcmoA to ER1821 cells (Baba et al., 2006) (C) Colony PCR was used to validate ER1821 ΔcmoA cells with primers flanking the endogenous cmoA locus. (D) Mspl assay (see methods) confirming >98% carboxymethylation of 5cxmC oligonucleotide standard. When interpreted with Figure 1C, this experiment additionally shows that 5cxmC completely blocks Mspl digestion, suggesting that this modification has a new gain-of-function ability to protect genomic DNA from restriction digestion in a way that 5mC cannot. (E) Representative LC-MS/MS standard curve for 5cxmC standard. (F) *In vivo* modification assay as described in Figure 1B. Upon overexpression, M.Mpel modifies its encoding plasmid using endogenous SAM or CxSAM. The modification can be assessed after plasmid isolation and restriction digestion. An Mspl-resistant modification appears only in the presence of both M.Mpel N374K and an intact *cmoA* gene.




Figure S2, related to Figure 3: Validation of *in vitro* **reagents.** (A) SDS-PAGE of M.Mpel enzymatic preps used in this study. (B) Chemical synthesis of CxSAM. (C) LC-MS ESI⁻ Total Ion Current (TIC) signal with observed mass of 443.5. In addition to the trace shown, HRMS was also obtained, identifying a mass of 443.1360 (mDa = -0.2, PPM = -0.5, Theoretical Mass: 443.1343). (D) HPLC purification of CxSAM showing single UV 260 nm peak.




Figure S3, related to Figure 3: Quantitative oligonucleotide assay. Assay design was previously validated with homologous methyltransferases (Nabel et al., 2017). a) M.Mpel N374K was incubated with excess SAM or CxSAM and a hemimethylated CpG substrate containing a fluorophore label as shown. ESI-MS was obtained to confirm carboxymethylation of the hemimethylated substrate (expected top strand: 8877.9, observed top strand: 8876.7). Hpall digest was used to visualize total modification of the top strand after bottom strand exchange. b) Representative oligonucleotide assay gels. c) Enzyme dilution curve showing quantitative, relative activities of M.Mpel WT and N374K towards SAM and CxSAM. Points represent mean \pm s.e. (n = 3 independent replicates). EC50 values were calculated, and 95% Confidence Intervals are reported in brackets.




Figure S4, related to Figure 4: Generalizability and applications of DNA carboxymethyltransferases. (A) LC-MS/MS detection of 5mC and 5cxmC nucleosides catalyzed by M.Mpel N374K and Dcm N436K *in vivo* overexpression. M.Mpel experiments show percent of CpG modification on plasmid DNA. Dcm experiments are shown as a percent of CCWGG modification on gDNA. The relative 5mC vs 5cxmC modification levels are also labelled. These are the same experimental data as Figure 2E and Figure 4D, respectively. (B) Growth curves for *dam/dcm E. coli* upon transformation with Dcm expression plasmids. Overnight cultures were diluted into a plate reader and monitored for 20 hrs using OD₆₀₀. Protein overexpression was induced with or without anhydrotetracycline (ATc). Points represent mean ± s.d. (n = 3 biological replicates). (C) SDS-PAGE of Dcm enzymatic preps used in this study. (D) Unmodified pUC19 plasmid DNA was incubated with an excess of SAM or CxSAM and 3-fold serial dilutions of Dcm WT or the N436K mutant to yield methylated or carboxymethylated DNA.

The negative control lane (*) contains the highest concentration of enzyme with no SAM or CxSAM substrate. Digestion with EcoRII fragments only unmodified DNA, allowing for visualization of digested substrate vs protected product. Dcm N436K transfers both CxSAM and SAM at comparable efficiency *in vitro* while Dcm WT only transfers SAM. (E) CpG carboxymethyltransferase can create 5-carboxymethylcytosine, which could permit differentiation of C, mC, and hmC by either enzymatic epigenetic sequencing methods or third generation sequencing (Schutsky et al., 2018).